Genetic testing for embryos in older women undergoing IVF
Official title: GEnetic Testing in Elective Single Embryo Transfer in Women of Advanced Maternal Age
Run by Genomic Prediction Inc. · NCT04167748 · Data updated 2026-11-12
This study is testing if using genetic testing on embryos can help women aged 35 to 40 have a better chance of getting pregnant through IVF.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 35 Years to 40 Years |
| Sex | Women only |
| Enrollment | 240 (estimated) |
| Sponsor | Genomic Prediction Inc. Industry-sponsored |
| Locations | 1 site (Margate, Florida) |
| Status | Recruiting |
| Started | March 5, 2021 |
| Main results expected | November 1, 2025 |
| Study ends | December 2026 |
| Registry record updated | August 26, 2025 |
| Trial ID | NCT04167748 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are women aged 35 to 40 who are undergoing IVF and have at least one evaluable blastocyst.
✕Probably not a fit
Patients with anovulatory PCOS, those utilizing donor oocytes, or those with a history of recurrent pregnancy loss or implantation failure may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The GETSET trial is a randomized controlled trial aimed at evaluating the outcomes of preimplantation genetic testing for aneuploidies (PGT-A) in women aged 35 to 40 undergoing elective single embryo transfer. A total of 240 participants will be recruited and divided into two groups: one receiving standard embryo transfer with untested embryos and the other receiving transfer of genetically tested euploid embryos. The study will assess the impact of PGT-A on conception rates and overall success in this demographic. Participants will undergo standard IVF procedures, including ovarian stimulation and embryo culture, followed by either a frozen embryo transfer or additional cycles based on the outcomes.
Why it matters
Potential benefit: If successful, this approach could significantly improve pregnancy rates and reduce the risk of miscarriage in older women undergoing IVF.
How similar studies have gone: Previous studies have shown promising results with preimplantation genetic testing, indicating potential benefits in similar populations.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women undergoing IVF of between 35 and 40 years of age at IVF cycle start * Utilization of Intracytoplasmic Sperm Injection ICSI * Utilization of ejaculated or testicular sperm * Utilization of autologous or donor sperm * All Controlled Ovarian Hyperstimulation (COH) protocols Exclusion criteria: * Patients with anovulatory Polycystic ovarian syndrome (PCOS) * Utilization of donor oocytes * Utilization of gestational carrier * Recurrent Pregnancy Loss (RPL) defined as ≥ 3 consecutive miscarriages * Recurrent Implantation Failure (RIF) defined as ≥ 3 more failed embryo transfers
Where it's running
-
IVF Florida Reproductive Associates
Margate, Florida, United States Recruiting
Study contacts
- Principal investigator: Nathan R Treff, PhD — Genomic Prediction
- Study coordinator: Nathan R Treff, PhD
- Email: nathan@genomicprediction.com
- Phone: (973) 529-4223
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI into Ultrasound Diagnostics in Reproductive Medicine
Researchers are testing AI tools that analyze transvaginal ultrasound images to help detect endometriosis, adenomyosis, uterine masses, and pregnancy-related receptivity in women aged 18-45.
-
Tadalafil to increase uterine lining and improve frozen embryo transfer success
This test sees if adding daily tadalafil to standard estrogen helps women with unexplained infertility using good-quality day‑5 frozen embryos get a thicker uterine lining and better transfer outcomes.
-
FET-LET-2x2: Testing natural vs medicated natural cycles for frozen embryo transfer
This study tests four approaches to preparing the uterus for frozen embryo transfer to see which yields the best pregnancy rate in women undergoing IVF.
-
Integrative care guided by biological aging markers for unexplained female infertility
This trial tests whether measuring telomeres and other biological aging markers can guide a personalized integrative treatment to help women aged 25–42 with persistent unexplained infertility improve their chances of pregnancy.
-
How fitness, heart health, and mental well-being relate to assisted fertility treatments
This study tries to see if physical activity, cardiorespiratory fitness, cardiovascular health, sleep, and stress affect pregnancy chances for women undergoing assisted fertility treatments.
-
How attitudes toward artificial intelligence relate to anxiety and quality of life in women receiving infertility treatment
This study will test whether women's attitudes toward artificial intelligence are linked to their anxiety and quality of life while undergoing infertility treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.